BiotechTube
Home/Organon (2)/Mike Casia
MC

Mike Casia

Interim Head of U.S. Commercial & Government Affairs

Organon (2)

Therapeutic Areas

Women's HealthBiosimilarsCardiovascularRespiratoryDermatologyNeurologyAutoimmune

Organon (2) Pipeline

DrugIndicationPhase
Elyea (relugolix combo)Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis PainApproved
PhexxiNon-hormonal ContraceptiveApproved
Orilissa (elagolix)Endometriosis PainApproved
Biosimilar AfliberceptOphthalmology (nAMD, DME)Filed
Biosimilar DenosumabOsteoporosis, Bone MetastasisPhase 3
Biosimilar RanibizumabOphthalmology (nAMD, DME, RVO)Phase 3
Biosimilar UstekinumabPlaque Psoriasis, Psoriatic Arthritis, IBDPhase 3
Biosimilar BevacizumabOncologyPhase 3

Leadership Team at Organon (2)

CC
Carrie Cox
Executive Board Chair
JM
Joseph Morrissey
Interim CEO
JC
Juan Camilo Arjona Ferreira
Head of R&D and Chief Medical Officer
JD
Juliana Drinane
Interim Head of Manufacturing and Supply
AF
Aaron Falcione
Chief Human Resources Officer
DK
Daniel Karp
Head of Corporate Development and Chief Strategy Officer
VN
Vittorio Nisita
Head of Enterprise Services & Solutions
RS
Rachel Stahler
Chief Digital and Growth Officer
NV
Nico Van Hoecke
Head of International Commercial
MW
Matthew Walsh
Chief Financial Officer
View full Organon (2) profile